First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

Kim Brøsen*, Lars F. Gram

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Four rapid extensive metabolizers (EM), four slow EM, and three poor metabolizers (PM) of sparteine were given single intravenous doses of 50 mg imipramine and desipramine. All subjects had previously taken single oral doses (100 mg) of imipramine and desipramine. The first-pass metabolism of imipramine and desipramine ranged from 23% to 73% and 0% to 48%, respectively, and was more pronounced for both drugs in EM than in poor metabolizers. The study suggested saturable 2-hydroxylation of imipramine and desipramine during the first-pass through the liver, especially in EM.

OriginalsprogEngelsk
TidsskriftClinical Pharmacology and Therapeutics
Vol/bind43
Udgave nummer4
Sider (fra-til)400-406
Antal sider7
ISSN0009-9236
DOI
StatusUdgivet - 1. jan. 1988

Fingeraftryk

Desipramine
Imipramine
Hydroxylation
Liver
Pharmaceutical Preparations

Citer dette

@article{8cbcdb3726354004b6c46db422c11eaf,
title = "First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype",
abstract = "Four rapid extensive metabolizers (EM), four slow EM, and three poor metabolizers (PM) of sparteine were given single intravenous doses of 50 mg imipramine and desipramine. All subjects had previously taken single oral doses (100 mg) of imipramine and desipramine. The first-pass metabolism of imipramine and desipramine ranged from 23{\%} to 73{\%} and 0{\%} to 48{\%}, respectively, and was more pronounced for both drugs in EM than in poor metabolizers. The study suggested saturable 2-hydroxylation of imipramine and desipramine during the first-pass through the liver, especially in EM.",
author = "Kim Br{\o}sen and Gram, {Lars F.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1038/clpt.1988.50",
language = "English",
volume = "43",
pages = "400--406",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "JohnWiley & Sons, Inc.",
number = "4",

}

First-pass metabolism of imipramine and desipramine : Impact of the sparteine oxidation phenotype. / Brøsen, Kim; Gram, Lars F.

I: Clinical Pharmacology and Therapeutics, Bind 43, Nr. 4, 01.01.1988, s. 400-406.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - First-pass metabolism of imipramine and desipramine

T2 - Impact of the sparteine oxidation phenotype

AU - Brøsen, Kim

AU - Gram, Lars F.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Four rapid extensive metabolizers (EM), four slow EM, and three poor metabolizers (PM) of sparteine were given single intravenous doses of 50 mg imipramine and desipramine. All subjects had previously taken single oral doses (100 mg) of imipramine and desipramine. The first-pass metabolism of imipramine and desipramine ranged from 23% to 73% and 0% to 48%, respectively, and was more pronounced for both drugs in EM than in poor metabolizers. The study suggested saturable 2-hydroxylation of imipramine and desipramine during the first-pass through the liver, especially in EM.

AB - Four rapid extensive metabolizers (EM), four slow EM, and three poor metabolizers (PM) of sparteine were given single intravenous doses of 50 mg imipramine and desipramine. All subjects had previously taken single oral doses (100 mg) of imipramine and desipramine. The first-pass metabolism of imipramine and desipramine ranged from 23% to 73% and 0% to 48%, respectively, and was more pronounced for both drugs in EM than in poor metabolizers. The study suggested saturable 2-hydroxylation of imipramine and desipramine during the first-pass through the liver, especially in EM.

UR - http://www.scopus.com/inward/record.url?scp=0023905440&partnerID=8YFLogxK

U2 - 10.1038/clpt.1988.50

DO - 10.1038/clpt.1988.50

M3 - Journal article

C2 - 3356084

AN - SCOPUS:0023905440

VL - 43

SP - 400

EP - 406

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -